Universe Pharmaceuticals Inc (UPC) FinancialsUPCUniverse Pharmaceuticals Inc

Universe Pharmaceuticals Inc (UPC) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Sales of TCMD products, accounting for 50.8% of total sales, equivalent to $9.37M. Another important revenue stream is Sales of third-party products. Understanding this composition is critical for investors evaluating how UPC navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Universe Pharmaceuticals Inc maintains a gross margin of 34.57%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -25.42%, while the net margin is -35.89%. These profitability ratios, combined with a Return on Equity (ROE) of 2.66%, provide a clear picture of how effectively UPC converts its operational activities into shareholder value.

In the context of the broader market, UPC competes directly with industry leaders such as AYTU and CLRB. With a market capitalization of $26.73M, it holds a leading position in the sector. When comparing efficiency, UPC's gross margin of 34.57% stands against AYTU's 55.10% and CLRB's N/A. Such benchmarking helps identify whether Universe Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

Universe Pharmaceuticals reported a revenue of $9.03 million with a net loss of $1.55 million for the first half of 2026, which is an improvement from a $3.28 million loss last year, showing signs of financial recovery.